Charles River Q3 revenue $895.9M (+20.5% YoY); non-GAAP EPS $2.70; updates 2021 guidance

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

2021-Q3 EPS reported $4.93 revenue$2,635,110,000

Revenue $895.9M, +20.5% YoY; organic growth 13.6% with contributions from all three segments.
GAAP EPS $2.01 (-1.0% YoY) includes $0.15 loss from venture investments; non-GAAP EPS $2.70 (+15.9%).
RMS segment revenue $171.3M (+12.7% YoY); DSA $531.8M (+15.3%); Manufacturing $192.9M (+48.1%).
2021 guidance: reported revenue growth 19.5%-20.5% (from 20.5%-22.5%); GAAP EPS raised to $7.05-$7.15; non-GAAP EPS $10.20-$10.30.
Completed divestitures of RMS Japan and CDMO Sweden on Oct 12; reduces Q4 revenue ~$20M and non-GAAP EPS <$0.10.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.